BCL-2 Inhibitor ABT-199 Monotherapy for High-Risk Relapsed/Refractory CLL or SLL


BCL-2 Inhibitor ABT-199 Monotherapy for High-Risk Relapsed/Refractory CLL or SLL
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (2/13/14)
Seymour JF et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Proc ASH 2013;Abstract 872.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at the UW Carbone Cancer Center in Madison, Wisconsin.